AH Calvert

Structure-Based design of 2-Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-Dependent kinases 1 and 2

Kerry L. Sayle, Johanne Bentley, F.Thomas Boyle et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 70 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +10

Kinetically-based multiple drug treatment for advanced head and neck cancer.

L A Price, B T Hill, AH Calvert et al. · BMJ · 1975 · 57 citations · Full text

Surgical Oncology, Neoadjuvant Therapy, Multiple Drug Regimen +17

Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

DR Newell, AH Calvert, KR Harrap et al. · British Journal of Clinical Pharmacology · 1983 · 52 citations · Full text

First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

Ruth Plummer, Mark R. Middleton, R. Wilson et al. · Journal of Clinical Oncology · 2005 · 44 citations

Immunology, Pathology, Pbl Parp Activity +16

Syntheses and thymidylate synthase inhibitory activity of the poly-.gamma.-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates

Graham M. F. Bisset, Krzysztof Pawełczak, Ann L. Jackman et al. · Journal of Medicinal Chemistry · 1992 · 34 citations · Full text